None

Rituximab (Rituximab) has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. The antitumor effect of rituximab relies in part on immune effector mechanisms, so resistance may be mediated not only by intrinsic tumor cell changes but also by the host immune environment.

If drug resistance occurs during use, doctors may recommend that patients repeat pathological examinations, imaging evaluations, or other relevant laboratory tests, and try other treatments or drugs depending on the specific situation. Sometimes, switching to a different class of medication or using other medications in combination may improve treatment response. If applicable, also consider participating in ongoing clinical trials for the disease, which often test new drugs or treatment strategies and may provide additional treatment opportunities for patients.

Rituximab has been launched in China and has entered the scope of Class B medical insurance. The use of rituximab must be carried out by doctors and medical staff. It is a strictly controlled drug and its purchase and use may be restricted. SpecificationsThe price of each box of 500mg/500mL may be around RMB 8,000, which is relatively expensive. Rituximab has also been launched overseas. The price of the original Indian version of 500mg/500mL per box may be around RMB 3,000 (the price may fluctuate due to exchange rates) . There are also generic rituximab drugs produced by other pharmaceutical companies in India. The price of 500mg/500mL per box may be around 1,500 yuan (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of domestic and foreign original drugs.